Balance Sheet
Accounts PayablesAssetsCommon EquityLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exousia Bio (LMMY) Cash & Equivalents (2022 - 2024)

Lamy (LMMY) has disclosed Cash & Equivalents for 3 consecutive years, with $1028.0 as the latest value for Q4 2024.

  • Quarterly Cash & Equivalents changed 0.0% to $1028.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1028.0 through Nov 2024, changed 0.0% year-over-year, with the annual reading at $1028.0 for FY2024, 86.91% down from the prior year.
  • Cash & Equivalents hit $1028.0 in Q4 2024 for Lamy, roughly flat from $1028.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $7855.0 in Q2 2023 to a low of $1028.0 in Q4 2023.
  • Historically, Cash & Equivalents has averaged $2203.1 across 3 years, with a median of $1028.0 in 2023.
  • Biggest YoY gain for Cash & Equivalents was 0.0% in 2024; the steepest drop was 86.91% in 2024.
  • Year by year, Cash & Equivalents stood at $1351.0 in 2022, then decreased by 23.91% to $1028.0 in 2023, then changed by 0.0% to $1028.0 in 2024.
  • Business Quant data shows Cash & Equivalents for LMMY at $1028.0 in Q4 2024, $1028.0 in Q3 2024, and $1028.0 in Q2 2024.